Next Article in Journal
The Cancer Stem Cell in Hepatocellular Carcinoma
Next Article in Special Issue
Recognition Dynamics of Cancer Mutations on the ERp57-Tapasin Interface
Previous Article in Journal
A Model of a Zebrafish Avatar for Co-Clinical Trials
Previous Article in Special Issue
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
Open AccessReview

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

1
International Centre for Cancer Vaccine Science (ICCVS), University of Gdańsk, 80-309 Gdańsk, Poland
2
Department of Pathomorphology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
3
Department of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
4
Department of Thoracic Surgery, Medical University of Gdańsk, 80-210 Gdańsk, Poland
5
Department of Oncology and Radiology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
6
Department of Biology, University of Rome "Tor Vergata", 00133 Rome, Italy
7
Department of Biology and Interdepartmental Center CIMETA, University of Rome "Tor Vergata", 00133 Rome, Italy
8
Laboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdańsk, 80-210 Gdańsk, Poland
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(3), 683; https://doi.org/10.3390/cancers12030683
Received: 30 January 2020 / Revised: 6 March 2020 / Accepted: 10 March 2020 / Published: 13 March 2020
(This article belongs to the Special Issue New Insights into Cancer Vaccines and Immunotherapy)
In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools. Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematologic malignancies, whereas adoptive transfer of autologous tumour infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma. These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumours. In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumours. We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumour-specificity and phenotype. Finally, we present strategies for improvement of anti-tumour potential of T cells, including combination therapies. View Full-Text
Keywords: adoptive cell therapy of cancer; immunotherapy; TCR therapy; neoantigens; antigen- specific T cells; T cell-based therapy of solid tumours adoptive cell therapy of cancer; immunotherapy; TCR therapy; neoantigens; antigen- specific T cells; T cell-based therapy of solid tumours
Show Figures

Figure 1

MDPI and ACS Style

Chruściel, E.; Urban-Wójciuk, Z.; Arcimowicz, Ł.; Kurkowiak, M.; Kowalski, J.; Gliwiński, M.; Marjański, T.; Rzyman, W.; Biernat, W.; Dziadziuszko, R.; Montesano, C.; Bernardini, R.; Marek-Trzonkowska, N. Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours. Cancers 2020, 12, 683.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop